Product Images Clopidogrel Bisulfate

The text describes a medication with the NDC code 50228-121-30, which contains clopidogrel isulae USP equivalent to 300 mg of clopdogrel base. The suggested adult dosage is not clearly readable, and the information should be obtained from the prescribing information. The medication comes in the form of 30 tablets and should be stored within the controlled room temperature specified by USP. The medication should be dispensed with a medication guide for each patient. The medication is manufactured by ScieGen Pharmaceutical, Inc.*

This is a description of a medication identified by its National Drug Code (NDC) 50228-121-05. The medication is Clopidogrel Bisulfate, USP equivalent to 300 mg of clopidogrel base, and it is supplied in the form of tablets. The storage temperature for the medication is 25°C (77°F) with permitted excursions to 15° to 30°C (59° to 86°F). Each bottle contains 500 tablets, and dispensing instructions are provided in the Medication Guide, which is separately supplied to each patient. The medication is manufactured by SclGen Pharmaceuticals, Inc, located in Hauppauge, NY 11788. The expiration date is not available.*

This is a description of the medication Clopidogrel Tablets, USP. Each tablet contains 7 875 mg of Clopidogrel tisuftate, USP, equivalent to 10.75 mg of Clopidogrel. The recommended adult dosage is not specified and the consumer should read the accompanying prescription information. The medication is manufactured by Steen Pharmaceuticals in Hauppauge, NY and is available in a bottle of 1000 tablets. It should be stored at 25° (17 excursions permitted 0 15° 0 30°C (6910 86F) [See USP Controlled Room Temperature]. The pharmacist should dispense the medication guide provided separately to each patient.*

Each tablet contains 97,875 mg of Clopidogrel bisulfate, USP which is equivalent to 75 mg of Clopidogrel base. The medication is for adult dosage only and should be stored at room temperature. The prescription should be accompanied by a Medication Guide for the patient. Manufactured by ScieGen Pharmaceuticals, Inc. 30 Tablets are available for Rx Only.*

This is a description of Clopidogrel bisulfate tablets that contains 97,875mg of USP and 0.75mg of clopidogrel base. The adult dosage should be read as per the prescribing information. It should be stored at a temperature of 25°C (77°F) with excursions permitted between 15-30°C (59-86°F) as guided by the USP-controlled room temperature. The label shows the manufacturing company- ScieGen Pharmaceuticals Inc. Hauppauge, WY 11788, the National Drug Code (NDC) 50228-124-05, and the revision date 05119. It is meant to be dispensed only through a prescription of a qualified healthcare professional with a separate medication guide for each patient.*

Each tablet contains 97.875mg of Clopidogrel bisulfate, USP. It is a medication used to prevent blood clots in individuals with certain cardiovascular conditions. The recommended adult dosage is not available in the given text. The medication should be stored at a temperature between 15-30°C (59-86°F) and the pharmacist must provide the patient with a medication guide. The tablets are manufactured by ScieGen Pharmaceuticals, Inc.*

This appears to be a figure showing the exposure of a medication called Clopidogrel Active Metabolite. The figure shows the effect of co-administering the medication with four different proton pump inhibitors (PPIs) - Deslansoprazole, Lansoprszole, Pantoprazole, and Omeprazole. The mean and 90% confidence intervals are shown for each PPI and their effect on the active metabolite AUC is depicted. The figure also includes a relative change graph for each PPI, showing the change in comparison to when the clopidogrel was administered alone.*

This is a graph showing the rates of cardiovascular death, myocardial infarction, and stroke in patients who received either a placebo plus aspirin or clopidogrel plus aspirin. The cumulative event rate is shown as a percentage over 12 months of follow-up. Other standard therapies were also used as appropriate. The data suggests a statistically significant difference in event rates between the two groups (P=0.00009).*

The text describes figures and data from the COMMIT study, comparing the use of placebo to clopidogrel in reducing the risk of death. The cumulative event rates for death are displayed in a graph, with data for both treatments presented as percentages. The results show a 7% proportional risk reduction for clopidogrel compared to placebo, with a p-value of 0.03. All treated patients in the study also received aspirin.*

This is a comparison between the effects of Placebo and Clopidogrel on patients. The proportion of individuals experiencing an event was 10.1% for Placebo and 9.2% for Clopidogrel. The associated proportional risk reduction for death is 7% (p=0.002). It also seems that the number of cases with re-infarction or stroke before the first discharge was 6. The rest of the text appears to be related to the time frame of the study as it measures the number of days since randomization.*

Figure 6 shows the effects of adding Clopidogrel with Aspirin in the COMMIT study across baseline and concomitant medication subgroups. The data includes various subgroups like gender, age, concomitant medication, etc. The primary endpoint is the combined outcome. No additional information is available in the text.*

This is a table showing the cumulative event rate for fatal or non-fatal vascular events after 6, 12, 18, and 24 months of follow-up using aspirin and clopidogrel. There is no additional information available.*